Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization
SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused...
MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics